![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Endocrine Research, Lilly Research Laboratories, Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana
Carnitine palmitoyltransferase 1
(CPT-1
) is a key regulator of the
oxidation of long-chain fatty acids in skeletal muscle and therefore a potential therapeutic target for diseases associated with defects in lipid metabolism such as obesity and type 2 diabetes. C75 [4-methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic acid] is an
-methylene-butyrolactone that has been characterized as both an inhibitor of fatty acid synthase and more recently, an activator of CPT-1 (Thupari et al., 2002). Using human CPT-1
expressed in the yeast Pichia pastoris, we demonstrate that C75 can activate the skeletal muscle isoform of CPT-1 and overcome inactivation of the enzyme by malonyl CoA, an important physiological repressor of CPT-1, and the malonyl CoA mimetic Ro25-0187 [{5-[2-(naphthalen-2-yloxy)-ethoxy]-thiophen-2-yl}-oxo-acetic acid]. We also show that C75 can activate CPT-1 in intact hepatocytes to levels similar to those achieved with inhibition of acetyl-CoA carboxylase, the enzyme that produces malonyl CoA. Finally, we demonstrate that concentrations of C75 sufficient for activation of CPT-1 do not displace bound malonyl CoA. We conclude that CPT-1 is an activator of human CPT-1
and other CPT-1 isoforms but that it does not activate CPT-1 through antagonism of malonyl CoA binding.
Address correspondence to: Dr. Craig Hammond, Lilly Research Laboratories, Lilly Corporate Center, Drop Code 0304, Indianapolis, IN 46285. E-mail: hammond_craig{at}lilly.com
This article has been cited by other articles:
![]() |
S. Aja, L. E. Landree, A. M. Kleman, S. M. Medghalchi, A. Vadlamudi, J. M. McFadden, A. Aplasca, J. Hyun, E. Plummer, K. Daniels, et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R352 - R361. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhou, W. F. Han, L. E. Landree, J. N. Thupari, M. L. Pinn, T. Bililign, E. K. Kim, A. Vadlamudi, S. M. Medghalchi, R. El Meskini, et al. Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells Cancer Res., April 1, 2007; 67(7): 2964 - 2971. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Wolfgang and M. D. Lane The Role of Hypothalamic Malonyl-CoA in Energy Homeostasis J. Biol. Chem., December 8, 2006; 281(49): 37265 - 37269. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wang, C. Cruciani-Guglielmacci, S. Migrenne, C. Magnan, V. E. Cotero, and V. H. Routh Effects of Oleic Acid on Distinct Populations of Neurons in the Hypothalamic Arcuate Nucleus Are Dependent on Extracellular Glucose Levels J Neurophysiol, March 1, 2006; 95(3): 1491 - 1498. [Abstract] [Full Text] [PDF] |
||||